JP2005524666A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524666A5
JP2005524666A5 JP2003572572A JP2003572572A JP2005524666A5 JP 2005524666 A5 JP2005524666 A5 JP 2005524666A5 JP 2003572572 A JP2003572572 A JP 2003572572A JP 2003572572 A JP2003572572 A JP 2003572572A JP 2005524666 A5 JP2005524666 A5 JP 2005524666A5
Authority
JP
Japan
Prior art keywords
active ingredient
inn
pharmaceutically acceptable
group
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003572572A
Other languages
English (en)
Japanese (ja)
Other versions
JP5150034B2 (ja
JP2005524666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/001876 external-priority patent/WO2003074055A1/en
Publication of JP2005524666A publication Critical patent/JP2005524666A/ja
Publication of JP2005524666A5 publication Critical patent/JP2005524666A5/ja
Application granted granted Critical
Publication of JP5150034B2 publication Critical patent/JP5150034B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003572572A 2002-03-06 2003-02-25 Pde4またはpde3/4インヒビターとヒスタミンレセプターアンタゴニストとの医薬組成物 Expired - Fee Related JP5150034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
EP02004987.0 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (3)

Publication Number Publication Date
JP2005524666A JP2005524666A (ja) 2005-08-18
JP2005524666A5 true JP2005524666A5 (enExample) 2006-03-02
JP5150034B2 JP5150034B2 (ja) 2013-02-20

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572572A Expired - Fee Related JP5150034B2 (ja) 2002-03-06 2003-02-25 Pde4またはpde3/4インヒビターとヒスタミンレセプターアンタゴニストとの医薬組成物

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2400670T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1482938E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1849468T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
NZ731344A (en) 2014-10-09 2018-08-31 Guangdong Raynovent Biotech Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AU781137B2 (en) * 1999-10-25 2005-05-05 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Similar Documents

Publication Publication Date Title
JP5769763B2 (ja) 治療用組成物およびその使用
EP1988898A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2023522010A5 (enExample)
EP1881832A2 (en) Use of flibanserin in the treatment of chronic pain
EA038531B1 (ru) Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
TW200916103A (en) Therapeutic compositions and methods
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びn−メチル−d−アスパラギン酸(nmda)受容体アンタゴニストを含む医薬組成物
JP2005508963A5 (enExample)
JP5362151B2 (ja) Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EP1791538A1 (en) Roflumilast and syk inhibitor combination and methods of use thereof
ES2400670T3 (es) Composición farmacéutica que comprende roflumilast y levocetirizina
JP2007524699A5 (enExample)
US20070167496A1 (en) Roflumilast and glycopyrronium combination
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
JP2006523652A (ja) 鬱病および/または不安の治療のためのパロキセチンおよび2−(s)−(4−フルオロ−2−メチル−フェニル)−ピペラジン−1−カルボン酸[1−(r)−(3,5−ビス−トリフルオロ−2−メチル−フェニル)−エチル]−メチルアミドを含む組み合わせ
JP2007518768A (ja) 有機化合物の組み合わせ物
RU2008108176A (ru) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
JP5702349B2 (ja) 去痰剤を含有する医薬組成物
JP5670006B2 (ja) 去痰剤を含有する医薬組成物
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物
WO2007126001A1 (ja) ロキソプロフェンを含有する鎮咳又は去痰のための医薬組成物